Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

被引：12
|
作者：
Johnson, B. [1 ]
Miller, V. [2 ]
Amler, L. [3 ]
Stern, H. [3 ]
Soh, C. [3 ]
O'Connor, P. [3 ]
Kabbinavar, F. [4 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] Genentech Inc, San Francisco, CA 94080 USA
[4] Univ Calif Los Angeles, Los Angeles, CA USA
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 03期
关键词：
D O I：
10.1016/S1359-6349(09)72037-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：5 / 6
页数：2
相关论文
共 50 条
  • [41] Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer
    Scagliotti, Giorgio
    von Pawel, Joachim
    Novello, Silvia
    Ramlau, Rodryg
    Favaretto, Adolfo
    Barlesi, Fabrice
    Akerley, Wallace
    Orlov, Sergey
    Santoro, Armando
    Spigel, David
    Hirsh, Vera
    Shepherd, Frances A.
    Sequist, Lecia V.
    Sandler, Alan
    Ross, Jeffrey S.
    Wang, Qiang
    von Roemeling, Reinhard
    Shuster, Dale
    Schwartz, Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (24) : 2667 - +
  • [42] Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy
    Volovat, Constantin
    Bondarenko, Igor M.
    Gladkov, Oleg A.
    Elsaesser, Reiner
    Buchner, Anton
    Bias, Peter
    Mueller, Udo
    SPRINGERPLUS, 2015, 4
  • [43] Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
    Gogishvili, Miranda
    Melkadze, Tamar
    Makharadze, Tamta
    Giorgadze, Davit
    Dvorkin, Mikhail
    Penkov, Konstantin
    Laktionov, Konstantin
    Nemsadze, Gia
    Nechaeva, Marina
    Rozhkova, Irina
    Kalinka, Ewa
    Gessner, Christian
    Moreno-Jaime, Brizio
    Passalacqua, Rodolfo
    Li, Siyu
    McGuire, Kristina
    Kaul, Manika
    Paccaly, Anne
    Quek, Ruben G. W.
    Gao, Bo
    Seebach, Frank
    Weinreich, David M.
    Yancopoulos, George D.
    Lowy, Israel
    Gullo, Giuseppe
    Rietschel, Petra
    NATURE MEDICINE, 2022, 28 (11) : 2374 - +
  • [44] Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51)
    Johnson, Elizabeth A.
    Marks, Randolph S.
    Mandrekar, Sumithra J.
    Hillman, Shauna L.
    Hauge, Mark D.
    Bauman, Mitchel D.
    Wos, Edward J.
    Moore, Dennis F.
    Kugler, John W.
    Windschitl, Harold E.
    Graham, David L.
    Bernath, Albert M., Jr.
    Fitch, Tom R.
    Soori, Gamini S.
    Jett, James R.
    Adjei, Alex A.
    Perez, Edith A.
    LUNG CANCER, 2008, 60 (02) : 200 - 207
  • [45] Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
    Miranda Gogishvili
    Tamar Melkadze
    Tamta Makharadze
    Davit Giorgadze
    Mikhail Dvorkin
    Konstantin Penkov
    Konstantin Laktionov
    Gia Nemsadze
    Marina Nechaeva
    Irina Rozhkova
    Ewa Kalinka
    Christian Gessner
    Brizio Moreno-Jaime
    Rodolfo Passalacqua
    Siyu Li
    Kristina McGuire
    Manika Kaul
    Anne Paccaly
    Ruben G. W. Quek
    Bo Gao
    Frank Seebach
    David M. Weinreich
    George D. Yancopoulos
    Israel Lowy
    Giuseppe Gullo
    Petra Rietschel
    Nature Medicine, 2022, 28 : 2374 - 2380
  • [46] CANOPY-A: A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating canakinumab as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC).
    Garon, Edward B.
    Ardizzoni, Andrea
    Barlesi, Fabrice
    Cho, Byoung Chul
    De Marchi, Pedro
    Goto, Yasushi
    Kowalski, Dariusz M.
    Lu, Shun
    Paz-Ares, Luis G.
    Spigel, David R.
    Spira, Alexander, I
    Thomas, Michael
    Leung, Mimi
    Baum, Jason
    Zhu, Zewen
    Oliveira Portella, Maria do Socorro
    Yang, James Chih-Hsin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Anti-angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial
    Lee, Siow Ming
    Woll, Penella J.
    Rudd, Robin
    Ferry, David
    O'Brien, Mary
    Middleton, Gary
    Spiro, Stephen
    James, Lindsay
    Ali, Kulsam
    Jitlal, Mark
    Hackshaw, Allan
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (15) : 1049 - 1057
  • [48] RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF EVOFOSFAMIDE (TH-302) IN COMBINATION WITH PEMETREXED IN ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
    Goldman, J.
    Belani, C.
    Novello, S.
    von Pawel, J.
    Csoszi, T.
    Orlov, S.
    Kroll, S.
    Pearce, T.
    ANNALS OF ONCOLOGY, 2015, 26
  • [49] DAILY ORAL PERIFOSINE IN COMBINATION WITH RADIOTHERAPY IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER: FIRST RESULTS OF A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER PHASE II STUDY
    Verheij, M.
    Karchmit, Y.
    Bakardjiev, S.
    Beliaukouski, V.
    Savu, M.
    Smickoska, S.
    Sindermann, H.
    Markivskyy, A.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S167 - S167
  • [50] RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF VANDETANIB MAINTENANCE THERAPY FOR ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC) FOLLOWING 1ST-LINE PLATINUM-DOUBLET CHEMOTHERAPY
    Ahn, Myung-Ju
    Park, Keunchil
    Ahn, Jin Seok
    Cho, Eun Kyung
    Lee, Dae Ho
    Lee, Gyeong Won
    Kang, Jin-Hyoung
    Kim, Sang-We
    Lee, Jong-Seok
    Lee, Ki Hyeong
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1251 - S1251
12345